Legal 500
Log in or register
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR

© 2026 Legalease Ltd. All rights reserved

Registered company in England & Wales No. 02427356 VAT GB 321 5727 22

Registered address: 188 Fleet Street, London, EC4A 2AG

  • Legal 500 Trust Centre
  • Contact Us
  • home
  • Market Intelligence
  • Search

7,150 results found

Use advanced search filters to refine your search

2 filters applied

Advanced search filters

Topics
Countries
Contributor

Start typing to add contributors

Content type
Show options
  • Article

    Celltrion USA Announces Submission Of BLA For Subcutaneous Infliximab Biosimilar

    On December 22, 2022, Celltrion USA announced that it submitted a Biologics License Application for a subcutaneous formulation of infliximab, CT-P13, to the U.S. Food and Drug Administration.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Podcast

    Chevron Doctrine & 340B (Podcast)

    Foley Hoag partner Ross Margulies recently joined the 340B Unscripted podcast for a discussion on the "Chevron Doctrine and 340B." In the episode, Ross provides background on Chevron deference...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Foley Hoag LLP
    Foley Hoag LLP
  • Article

    Clarus Ventures Seeks To Raise $375 Million For New Life Sciences VC Fund

    Clarus Ventures has set out to raise $375 million for a new life sciences VC fund.
    United StatesFood, Drugs, Healthcare, Life Sciences
    McGuireWoods LLP
    McGuireWoods LLP
  • Article

    CMS Sets January 1, 2018 Effective Date for Expansion of Bundled Payment Programs

    In March, as discussed here, the Centers for Medicare & Medicaid Services (CMS) published an interim final rule that delayed the effective date of planned cardiac care bundled payment initiatives and the expansion of the Comprehensive Care for Joint Replacement (CJR) Model from July 2017 to October 2017.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Day Pitney LLP
    Day Pitney LLP
  • Article

    Congressional Panels Examining Pharmaceutical Distribution Systems, FDA Drug User Fees

    Two Congressional committees are holding hearings this week on FDA user fees: a March 21 Senate Health, Education, Labor, and Pensions Committee hearing and a March 22 Energy and Commerce Subcommittee on Health hearing.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Reed Smith
    Reed Smith
  • Article

    Could COVID-19 Data Help Medical Device Manufacturers Accelerate The FDA Approval Process?

    Still, the real-world evidence (RWE) gained about these devices while marketed under the EUA need not be lost with the passing of the pandemic.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Duane Morris LLP
    Duane Morris LLP
  • Article

    Could Medical Device Manufacturers Accelerate The FDA Approval Process By Using COVID-19 Data?

    Were it not for these EUAs, these manufacturers would be unable to market their devices, as their FDA applications would still be pending.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Duane Morris LLP
    Duane Morris LLP
  • Article

    Critical Medical Device Series: Part VII FDA's And FTC's Roles In MedTech Promotion And Advertising

    As the second Trump administration ushers in changes across federal agencies, medical device companies must stay vigilant in their promotional and advertising practices.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Arnold & Porter
    Arnold & Porter
  • Article

    Denosumab Biosimilar Updates

    Celltrion Submits Denosumab BLA to FDA: On November 30, 2023, it was reported that Celltrion had completed submission of its application to the FDA for CT-P41...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    Denosumab Clinical Trial Updates

    The Big Molecule Watch is monitoring Phase III clinical trials involving denosumab biosimilars. Here we report on the results of two recently completed studies.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    Desjardins Discusses Current Goals, Future Of Device Industry, And FDA Priorities For 2024

    Life Sciences & Healthcare Regulatory partner Philip Desjardins, who recently rejoined the firm, was profiled in the Medtech Insight article...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Arnold & Porter
    Arnold & Porter
  • Video

    Digital Transformation In The Life Sciences (Video)

    The convergence of life sciences and technology continues to have a tremendous impact across the life sciences industry. Innovation is moving at a rapid pace, investment across the sector is at an all-time high...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Morrison Foerster
    Morrison Foerster
  • Article

    Discovery Ruling In District Of Minnesota May Have Far-Reaching Implications For FCA Defendants

    The FCA creates liability for persons or entities found to have knowingly submitted false claims to the government or having caused others to do so.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Duane Morris LLP
    Duane Morris LLP
  • Article

    Do You Know Where Your Pharmaceuticals Are From? Navigating The "Country Of Origin" Question For Pharmaceutical Products

    Drug and medical device manufacturers are often faced with difficult challenges in sorting out the country of origin for their products.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Reed Smith
    Reed Smith
  • Article

    Drug, Device Makers Could Get Hit for Not Reporting Payments to Doctors

    Day Pitney healthcare attorney Eric Fader was quoted in an April 12 article, "Drug, Device Makers Could Get Hit for Not Reporting Payments to Doctors," in Bloomberg BNA's Life Sciences Law & Industry Report and other publications.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Day Pitney LLP
    Day Pitney LLP
  • Article

    Electronic Distribution Of Prescribing Information For Prescription Drugs & Biologicals

    The FDA published a proposed rule on December 18, 2014 that would require electronic distribution of the prescribing information intended for health care professionals, which is currently distributed in paper form on or within the prescription drug or biological product packaging.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Reed Smith
    Reed Smith
  • Article

    Eli Lilly Looks To Medical Records To Go After Compounders

    In an effort to gain more information regarding whether there is appropriate compounding to support weight loss drug products, Eli Lilly has decided to request medical records from users. This marks a new effort by Lilly...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Buchanan Ingersoll & Rooney
    Buchanan Ingersoll & Rooney
  • Article

    Eli Lilly To Acquire Merida Biosciences

    Eli Lilly announces a definitive agreement to acquire Merida Biosciences for up to $2.875 billion in cash, gaining access to an innovative antibody-engineering platform that selectively targets pathogenic autoantibodies in autoimmune and allergic diseases. The acquisition includes Merida's lead program MER511, currently in Phase 1 development for Graves' disease and thyroid eye disease, along with earlier-stage programs addressing food allergy, asthma, and kidney disease.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    EMA Seeks Input On A "Tailored Clinical Approach" In Biosimilar Development

    On April 1, 2025, the European Medicines Agency opened the consultation period for its draft reflection paper on a tailored clinical approach in biosimilar development.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    Erroneous Country Of Origin Determinations May Result In Significant FCA Penalties For Medical Device Companies

    Country of origin labeling issues can be exceedingly complex, as we have noted before. Several manufacturers have recently paid multi-million dollar settlements for alleged misstatements about their products’ country of origin.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Reed Smith
    Reed Smith
  • Showing 401–420 of 7150 results

    PreviousNext
    Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics